InMed Initiates Program Targeting Epidermolysis Bullosa Simplex

InMed Pharmaceuticals Inc. added a new therapy to its pipeline: INM-750, for the treatment of Epidermolysis bullosa simplex(EBS), a rare genetically inherited skin disorder. INM-750 is designed to suppress pathological skin growth, differentiation, and inflammation that are signature characteristics of EBS.

InMed anticipates commencing pre-clinical studies of INM-750 in February 2015 with initial data expected by Q2 2015. The company says that its initiation of INM-750 signals InMed’s entry into the dermatological market and adds to its advancing pipeline of cannabis-based therapeutics, which includes CTI-805 for glaucoma and CT-091 for arthritis, both of which are expected to enter human clinical studies in 2015. 

"We are pleased to continue the strategic diversification of our pipeline by adding a third therapy identified by our proprietary platform technology," said Craig Schneider, President & CEO of InMed. "The discovery of INM-750 furthers our corporate strategy of developing therapies for diseases that may be approved for Orphan Drug Designation."

Sazzad Hossain, PhD, MSc, Chief Scientific Officer of InMed, stated, "EBS is a rare keratin mutation-related disease with no FDA approved treatment. The only options available to patients are wound care, pain management, and preventative bandaging. More severe forms of the disease lead to scarring, disfigurement, disability, and early death, usually before the age of 30."

Craig Schneider concluded, "We are working rapidly to advance the development of INM-750 to address this significant unmet medical need."